sorafenib has been researched along with Osteosarcoma in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 8 (32.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, Y; Dong, S; Han, W; Han, Y; Li, Z; Liu, S; Luo, Z; Ni, D; Niu, L; Pi, R; Song, L; Sun, D; Wei, Q; Zhao, Y; Zhu, T | 1 |
| Hu, X; Jian, C; Li, D; Li, P; Li, Y; Li, Z; Yi, W; Yu, A; Yuan, Y; Zhao, Y | 1 |
| Huyan, T; Lou, C; Shang, P; Wang, S; Zhang, H | 1 |
| Yang, YT; Yuzbasiyan-Gurkan, V | 1 |
| Bao, Q; Hu, F; Liu, Z; Wang, J; Wen, J; Yu, P; Zhang, W | 1 |
| Kang, T; Liao, D; Liu, W; Wang, X; Yu, X; Zeng, C; Zhang, R; Zhang, Y; Zhong, L | 1 |
| Arakawa, A; Iwata, S; Kawai, A; Kobayashi, E; Kumamoto, T; Maniwa, J; Nakajima, M; Ogawa, C; Shirakawa, N; Sugiyama, M; Tanimura, K; Tao, K; Watanabe, Y; Yoneda, A | 1 |
| Belt, P; Bouvet, M; Chawla, SP; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Kline, Z; Miwa, S; Miyake, K; Oshiro, H; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N | 1 |
| Fu, BS; Hsu, FT; Lin, KH; Pan, PJ; Tsai, JJ; Weng, MC; Wu, CH | 1 |
| DeVere White, RW; Duan, Z; Ho, PY; Jian, C; Lam, KS; Lara, PN; Qiu, JX; Tu, MJ; Wun, T; Yu, AM; Yu, AX; Zhang, Q | 1 |
| Armstrong, AE; Leavey, PJ; Reichek, J; Walterhouse, DO; Walz, AL | 1 |
| Hayashi, K; Igarashi, K; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N | 1 |
| Bouvet, M; Chawla, SP; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N | 1 |
| Aglietta, M; Alberghini, M; Basiricò, M; Bruno, S; Capozzi, F; D'Ambrosio, L; Dell'Aglio, C; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Marchiò, S; Picci, P; Pignochino, Y; Sangiolo, D; Soster, M; Torchiaro, E | 1 |
| Burger, S; Gallè, B; Mair, G; Miller, I; Steinborn, R; Walter, I; Wolfesberger, B | 1 |
| Aglietta, M; Asaftei, SD; Bertulli, R; Biagini, R; Capozzi, F; Casali, PG; D'Ambrosio, L; Fagioli, F; Ferraresi, V; Ferrari, S; Gambarotti, M; Grignani, G; Marchesi, E; Palmerini, E; Picci, P; Pignochino, Y; Sangiolo, D; Tamburini, A | 1 |
| Bode, B; Cathomas, R; Fuchs, B; Rothermundt, C; Schwitter, M; von Moos, R | 1 |
| Dong, R; Kang, M; Yang, Q; Zhang, S; Zhao, J | 1 |
| Davidoff, AM; Interiano, RB; McCarville, MB; Navid, F; Sandoval, J; Wu, J | 1 |
| Dinçaslan, H; Ensari, A; Kiremitçi, S; Özçakar, ZB; Taktak, A; Yalçınkaya, F; Yılmaz, S | 1 |
| Chishima, T; Dry, SM; Eilber, FC; Elliott, I; Endo, I; Federman, N; Hiroshima, Y; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Matsuyama, R; Murakami, T; Nelson, SD; Russell, T; Singh, A; Tanaka, K; Yanagawa, J; Zhang, Y; Zhao, M | 1 |
| Egerbacher, M; Gerner, W; Heiduschka, G; Skalicky, M; Thalhammer, JG; Tonar, Z; Walter, I; Wolfesberger, B | 1 |
| Aglietta, M; Alberghini, M; Bottos, A; Bruno, S; Bussolino, F; Camussi, G; Cavalloni, G; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Migliardi, G; Motta, M; Picci, P; Pignochino, Y; Tapparo, M; Torchio, B | 1 |
| Aglietta, M; Asaftei, SD; Casali, PG; D'Ambrosio, L; Dileo, P; Fagioli, F; Ferrari, S; Grignani, G; Mercuri, M; Palmerini, E; Picci, P; Pignochino, Y | 1 |
| Bai, XZ; Han, XR; Sun, Y | 1 |
1 review(s) available for sorafenib and Osteosarcoma
| Article | Year |
|---|---|
Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Drug Therapy; Furans; Humans; Immunotherapy, Adoptive; Indazoles; Ipilimumab; Ketones; Nivolumab; Osteosarcoma; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Trabectedin | 2019 |
2 trial(s) available for sorafenib and Osteosarcoma
| Article | Year |
|---|---|
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Disease-Free Survival; Everolimus; Female; Humans; Intention to Treat Analysis; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Niacinamide; Osteosarcoma; Phenylurea Compounds; Sirolimus; Sorafenib; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2015 |
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Osteosarcoma; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Failure; Treatment Outcome; Young Adult | 2012 |
22 other study(ies) available for sorafenib and Osteosarcoma
| Article | Year |
|---|---|
Novel 2-phenyl-3-(Pyridin-2-yl) thiazolidin-4-one derivatives as potent inhibitors for proliferation of osteosarcoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Osteosarcoma; Pyridines; Structure-Activity Relationship; Thiazolidines | 2022 |
Chidamide augment sorafenib-derived anti-tumor activities in human osteosarcoma cells lines and xenograft mouse model.
Topics: Aminopyridines; Animals; Benzamides; Bone Neoplasms; Cell Line, Tumor; Heterografts; Histone Deacetylase Inhibitors; Humans; Mice; Osteosarcoma; Sorafenib | 2022 |
12 T high static magnetic field suppresses osteosarcoma cells proliferation by regulating intracellular ROS and iron status.
Topics: Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cisplatin; Humans; Iron; Magnetic Fields; Osteosarcoma; Reactive Oxygen Species; Sorafenib | 2022 |
Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Cell Line; Cell Line, Tumor; Cisplatin; Dog Diseases; Dogs; Doxorubicin; Humans; Osteosarcoma; Sorafenib | 2022 |
Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma.
Topics: Animals; B7-H1 Antigen; Bone Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Doxorubicin; Humans; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Osteosarcoma; Sorafenib; Tumor Microenvironment; Up-Regulation | 2023 |
Targeting the Lysosomal Degradation of Rab22a-NeoF1 Fusion Protein for Osteosarcoma Lung Metastasis.
Topics: Humans; Lung Neoplasms; Lysosomes; Oncogene Proteins, Fusion; Osteosarcoma; Protein Kinases; rab GTP-Binding Proteins; Sorafenib; Ubiquitin-Protein Ligases | 2023 |
Safety and efficacy of multiple tyrosine kinase inhibitors in pediatric/adolescent and young adult patients with relapsed or refractory osteosarcomas: A single-institution retrospective analysis.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Child; Everolimus; Female; Humans; Male; Neoplasm Recurrence, Local; Osteosarcoma; Phenylurea Compounds; Retrospective Studies; Sorafenib; Tyrosine Kinase Inhibitors; Young Adult | 2023 |
Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Everolimus; Humans; Mice; Osteosarcoma; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
Sorafenib Induces Apoptosis and Inhibits NF-κB-mediated Anti-apoptotic and Metastatic Potential in Osteosarcoma Cells.
Topics: Apoptosis; Bone Neoplasms; Cell Line, Tumor; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; NF-kappa B; Osteosarcoma; Sorafenib | 2021 |
Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Disease Models, Animal; DNA; Doxorubicin; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Osteosarcoma; Phenylurea Compounds; RNA; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Child; Drug Resistance, Neoplasm; Humans; Male; Mutation; Osteosarcoma; Prognosis; Receptor, Platelet-Derived Growth Factor alpha; Salvage Therapy; Sorafenib | 2019 |
Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Disease Models, Animal; Doxorubicin; Drug Resistance, Neoplasm; Humans; Mice; Neoplasm Recurrence, Local; Osteosarcoma; Piperazines; Pyridines; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Survival; Chick Embryo; Everolimus; Female; Flow Cytometry; Humans; Immunohistochemistry; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred NOD; Mice, SCID; Multiprotein Complexes; Neovascularization, Pathologic; Niacinamide; Osteosarcoma; Phenylurea Compounds; Reactive Oxygen Species; RNA Interference; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Niacinamide; Oligonucleotide Array Sequence Analysis; Oncogene Proteins v-fos; Osteosarcoma; Phenylurea Compounds; Receptors, CXCR4; S100 Calcium-Binding Protein A4; S100 Proteins; Sorafenib; Transcriptome | 2014 |
RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward?
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Denosumab; Drug Resistance, Neoplasm; Humans; Male; Niacinamide; Osteosarcoma; Phenylurea Compounds; Prognosis; RANK Ligand; Remission Induction; Salvage Therapy; Sorafenib | 2015 |
Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; G1 Phase; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Osteosarcoma; Phenylurea Compounds; Phosphorylation; Reactive Oxygen Species; Resting Phase, Cell Cycle; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Bevacizumab; Bone Neoplasms; Child; Child, Preschool; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Niacinamide; Osteosarcoma; Phenylurea Compounds; Pneumothorax; Sarcoma, Ewing; Sarcoma, Synovial; Sorafenib; Wilms Tumor; Young Adult | 2015 |
Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cisplatin; Doxorubicin; Humans; Ifosfamide; Male; Methotrexate; Nephrotic Syndrome; Niacinamide; Osteosarcoma; Phenylurea Compounds; Proteinuria; Remission, Spontaneous; Sorafenib; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A; Withholding Treatment | 2016 |
Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug.
Topics: Adolescent; Animals; Antineoplastic Agents; Biological Therapy; Bone Neoplasms; Drug Resistance, Neoplasm; Humans; Male; Mice, Nude; Molecular Targeted Therapy; Necrosis; Niacinamide; Osteosarcoma; Phenylurea Compounds; Protein Kinase Inhibitors; Salmonella typhimurium; Sorafenib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Bone Neoplasms; Caspase 3; Cell Count; Cell Line, Tumor; Dog Diseases; Dogs; Flow Cytometry; Ki-67 Antigen; Microscopy, Electron, Transmission; Niacinamide; Osteosarcoma; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib | 2010 |
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Division; Cell Line, Tumor; Cytoskeletal Proteins; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Osteosarcoma; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2009 |
The anti-tumor role and mechanism of integrated and truncated PDCD5 proteins in osteosarcoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Proteins; Niacinamide; Osteosarcoma; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; ras Proteins; Signal Transduction; Sorafenib; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |